Forest Services
Introduction: Identification of SCAN in Parkinson’s Disease
In early 2024, neuroscientists identified a novel brain network termed the Subthalamic-Cortical-Amygdala Network (SCAN) implicated in Parkinson’s disease (PD) pathophysiology. Functional MRI studies revealed altered connectivity within SCAN components—the subthalamic nucleus, cortical regions, and amygdala—in PD patients, highlighting its role in motor and emotional regulation (Nature Neuroscience, 2024; The Hindu, 2024). This discovery provides a network-level understanding beyond classical dopamine-centric models, offering new avenues for diagnosis and treatment.
UPSC Relevance
- GS Paper 3: Science and Technology – Neurodegenerative diseases, brain research advancements
- GS Paper 2: Health Governance – Regulatory frameworks for biomedical research and clinical trials
- GS Paper 3: Economy – Economic burden of neurological disorders and healthcare expenditure
- Essay Topics – Science and Technology developments impacting public health
Pathophysiological Insights from SCAN Network Discovery
SCAN integrates the subthalamic nucleus, a key basal ganglia node, with cortical areas responsible for motor planning and the amygdala involved in emotional processing. This triadic interaction explains motor symptoms and non-motor manifestations such as anxiety and depression in PD (Nature Neuroscience, 2024). The network dysfunction challenges the dopamine-centric view by implicating broader circuit-level disruptions.
- Functional MRI demonstrated reduced connectivity strength within SCAN in PD patients compared to controls (The Hindu, 2024).
- SCAN abnormalities correlate with symptom severity, suggesting biomarker potential.
- Emotional dysregulation in PD linked to amygdala involvement within SCAN.
- Subthalamic nucleus remains a prime target for Deep Brain Stimulation (DBS), effective in 70% of advanced PD cases (JAMA Neurology, 2023).
Regulatory and Ethical Framework Governing Parkinson’s Research in India
Neuroscience research involving human subjects in India is regulated by the Indian Council of Medical Research (ICMR) National Ethical Guidelines for Biomedical and Health Research involving Human Participants (2017). Clinical trials for Parkinson’s therapeutics fall under the Drugs and Cosmetics Act, 1940 and its Rules, especially Section 3 and Schedule Y, which specify requirements for safety, efficacy, and ethical conduct.
- ICMR guidelines mandate informed consent, data privacy, and risk minimization in PD research.
- Schedule Y outlines clinical trial phases and regulatory approvals for novel Parkinson’s drugs and devices.
- Ethical oversight committees ensure compliance with international standards.
- DBT’s National Brain Research Centre (NBRC) facilitates translational research aligning with these regulations.
Economic Burden and Market Dynamics of Parkinson’s Disease in India
Parkinson’s disease affects approximately one million Indians, with a prevalence of 100-150 per 100,000 population (Lancet Neurology, 2022). Treatment costs average INR 50,000 annually per patient, imposing a significant economic burden on patients and healthcare systems. The Indian neurological disorder market, including PD, is projected to grow at a CAGR of 12.5%, reaching USD 1.2 billion by 2027 (Frost & Sullivan, 2023).
- Government allocated INR 1,500 crore in 2023-24 for neurodegenerative disease research via DBT’s NBRC.
- Cost of advanced therapies like DBS limits accessibility for many patients.
- Indirect costs include loss of productivity and caregiver burden.
- Global PD market valued at USD 4.7 billion in 2023, expected to reach USD 7.2 billion by 2030 (Grand View Research, 2023).
Comparison: India vs Japan in Parkinson’s Disease Management
| Aspect | India | Japan |
|---|---|---|
| Parkinson’s Prevalence | 100-150 per 100,000 | Approx. 160 per 100,000 |
| Patient Registries | Absent; no centralized database | Nationwide neurodegenerative disease registries operational |
| Deep Brain Stimulation (DBS) Accessibility | Limited availability; high cost barriers | Advanced DBS programs widely accessible |
| Quality of Life Improvement | Data scarce; suboptimal outcomes | 15% improvement over five years (Japan Ministry of Health, 2023) |
| Research Infrastructure | Emerging; NBRC and AIIMS leading | Well-established, integrated research and clinical networks |
Critical Gaps in India’s Parkinson’s Disease Ecosystem
India lacks a centralized PD patient registry and standardized early diagnostic protocols incorporating novel biomarkers such as SCAN network activity. This results in delayed diagnosis and treatment initiation, reducing therapeutic efficacy. Additionally, limited DBS accessibility and inadequate integration of emotional symptom management contribute to suboptimal patient outcomes.
- Absence of nationwide data hampers epidemiological tracking and resource allocation.
- Diagnostic protocols rely heavily on clinical symptoms and dopamine markers, ignoring network-level dysfunctions.
- Financial and infrastructural barriers restrict advanced therapy dissemination.
- Need for training clinicians on SCAN-related diagnostics and interventions.
Significance and Way Forward
- Incorporate SCAN network biomarkers into early PD diagnosis to enable timely interventions.
- Develop a centralized PD registry to facilitate data-driven policymaking and research.
- Expand DBS programs and subsidize costs to improve accessibility.
- Enhance interdisciplinary research linking motor and emotional symptoms via SCAN.
- Strengthen ethical oversight and streamline clinical trial approvals under ICMR and Drugs and Cosmetics Act.
- SCAN includes the subthalamic nucleus, cortical regions, and amygdala.
- SCAN dysfunction explains only the motor symptoms of Parkinson’s disease.
- Functional MRI studies identified altered SCAN connectivity in Parkinson’s patients.
Which of the above statements is/are correct?
- The Indian Council of Medical Research (ICMR) guidelines regulate ethical conduct in PD research.
- The Drugs and Cosmetics Act, 1940, does not cover clinical trials for Parkinson’s therapeutics.
- Schedule Y of the Drugs and Cosmetics Rules specifies clinical trial requirements for PD drugs.
Which of the above statements is/are correct?
FAQs
What is the SCAN network and its components?
SCAN stands for Subthalamic-Cortical-Amygdala Network, comprising the subthalamic nucleus, cortical motor areas, and the amygdala. It regulates motor functions and emotional processing, both affected in Parkinson’s disease (Nature Neuroscience, 2024).
How was the SCAN network discovered?
SCAN was identified through functional MRI studies showing altered connectivity patterns in Parkinson’s patients compared to healthy controls, indicating its role in disease pathophysiology (The Hindu, 2024).
What regulatory frameworks govern Parkinson’s disease research in India?
Parkinson’s research in India is regulated by ICMR’s National Ethical Guidelines (2017) and the Drugs and Cosmetics Act, 1940 with Schedule Y, which oversee ethical conduct and clinical trial protocols.
What are the economic challenges of Parkinson’s disease treatment in India?
Treatment costs average INR 50,000 per patient annually, with limited access to advanced therapies like DBS. The neurological disorder market is growing but still constrained by affordability and infrastructure (Frost & Sullivan, 2023).
How does India’s Parkinson’s disease management compare to Japan’s?
Japan has higher PD prevalence but benefits from nationwide registries, advanced DBS programs, and better quality of life improvements. India lacks centralized registries and widespread DBS access, leading to suboptimal outcomes (Japan Ministry of Health, 2023).
About LearnPro Editorial Standards
LearnPro editorial content is researched and reviewed by subject matter experts with backgrounds in civil services preparation. Our articles draw from official government sources, NCERT textbooks, standard reference materials, and reputed publications including The Hindu, Indian Express, and PIB.
Content is regularly updated to reflect the latest syllabus changes, exam patterns, and current developments. For corrections or feedback, contact us at admin@learnpro.in.